PATHOPHYSIOLOGICAL RATIONALE FOR THE USE OF A NEW AMINO ACID MIXTURE FOR LIVER DAMAGE
Main Article Content
Abstract
Objective: determination of the pathophysiological validity of the use of the new amino acid mixture for damage to the liver.Materials methods. Acute heliotrin intoxication is reproduced by single administration of rats subcutaneous sub-lethal doses of heliotrin, prepared at the rate of 40 mg per 100 g of body weight. Toxic hepatitis is reproduced by subcutaneous administration of heliotrin. Results. During the reproduction of experimental toxic hepatitis by introducing heliotrin, it was found that the HIF-1 content was on average 0.101667 ± 0.0022 ng /l. In blood plasma, the average HIF-1 was 0.2136 ± 0.0066 ng / L. Such indicators are explained by the effect of heliotrin on the liver and, above all, on hepatocytes, in which mitochondria are experiencing an oxygen deficiency. Thus, HIF-1 acts as an early biomarker of oxygen tissue deficiency and since it causes angiogenesis, the strengthening of this gene in experimental animals with ischemia can contribute to the proliferation of vessels necessary for oxygenation. Conclusions: The developed aminoacid mixture in terms of the effectiveness of the impact on the development and course of experimental toxic hepatitis surpasses traditional methods of treatment, which is proved by the study.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Бабаджанова Ш.А. Курбонова З.Ч. Изучение агрегационной функции тромбоцитов у больных с циррозами печени вирусной этиологии // Сборник материалов III международного молодежного научно-практического форума «Медицина будущего от разработки до внедрения». – Оренбург, 2019. - С 482. 2. Бабаджанова Ш.А. Курбонова З.Ч. Сравнительная эффективность препаратов Аденозина и АТФ при лечении приобретенной тромбоцитопатии // III международный молодежный научно-практический форум «Медицина будущего от разработки до внедрения». Оренбург, 2019. – C. 483. 3. KurbonovaZ.Ch.,Babadjanova Sh.A. Violations of coagulative hemostasis in patients with liver cirrhosis of the viral etiology.European science review. 2018,7-8:122-125. 4. Курбонова З.Ч. Вирус этиологияли сурункали гепатит ва жигар циррозида гемостаз тизими бузилиши хусусиятлари: автореф. Дис. Кан. Мед. Наук. – Тошкент, 2019. -45 с. 5. Курбонова З.Ч., Бабаджанова Ш.А. Функциональная характеристика тромбоцитов у больных циррозами печени вирусной этиологии // Российская наука в современном мире. – Москва, 2019. – С. 47-48.
Курбанова З.Ч. Evolution of the condition of the vascular – thrombocytic hemostasis system in the patients with cirrhosis of the liver // Young scientist day topical issues in medicine. – 2016. –С. 161-162. 7. Курбонова З.Ч. Нарушение сосудисто–тромбоцитарного звена гемостаза у больных с хроническими гепатитами и циррозом печени вирусной этиологии // Журнал проблемы биологии и медицины. – 2018. - № 3 (102). – С. 40-43. 8. Курбонова З.Ч., Бабаджанова Ш.А. Нарушение системы гемостаза при хронических диффузных заболеваниях печени: монография. Тошкент, "Ҳилол нашр" босмахонаси, 2021. С. 106-108. 9. Курбонова З.Ч., Бабаджанова Ш.А. Диагностика и лечение приобретенной тромбоцитопатии: методические рекомендации. Тошкент, 2018. С. 14-15. 10. Саидов A.Б., Сайфутдинова З.А., Каримов Х.Я. Лекарственно-индуцированный токсический гепатит: современные воззрения // Назарий ва клиник тиббиёт, 2021. -№3. – Б. 52-58
Roytberg G. E. Internal diseases. Laboratory and instrumental diagnostics: training. manual / G. E. Roytberg, A. AT. Strutynsky. – 2nd ed., Outskirts. and additional – Moscow: MEDpress-inform, 2011. – 800 s
Leites, Yu. G. Modern technologies in the diagnosis of gastroenterological diseases / Yu. G. Leites, E. AT. Marchenko. – Access mode: http://www.gastroscan.ru ( date of circulation: 06/10/2013 ).
Chen EY, Fujinaga M, Giaccia AJ. Hypoxic microenvironment within an embryo induces apoptosis and is essential for proper morphological development. Teratology. 1999; 60: 215 – 225.
Cramer T, Yamanishi Y, Clausen BE, et al. HIF-1α is essential for myeloid cell-mediated inflammation. Cell. 2003; 112: 645 – 657.
Date T, Mochizuki S, Belanger AJ, et al. Expression of constitutionally stable hybrid hypoxia-inducible factor-1α protects cultured rat cardiomyocytes against simulated ischemia-reperfusion injury. Am J Physiol. 2005; 288: C314 – C320.
Fox S.B., Braganca J, Turley H, et al. CITED4 inhibits hypoxia-activated transcription in Cancer Cells, and its cytoplasmic location in breast cancer is associated with elevated expression of tumor cell hypoxia-inducible factor 1α Cancer Res. 2004; 64: 6075 – 6081.
Genbacev O, Zhou Y, Ludlow JW, Fisher SJ. Regulation of human placental development by oxygen tension. Science. 1997; 277: 1669 – 1672.
Giannini E. G., Testa R., Savarino V. Liver enzyme alteration: a guide for clinicians // Canadian Medical Association Journal ( CMAJ ). – 2005. – Vol. 172. – P. 367-379.
Hewitson K.S., Schofield C.J. The HIF pathway as a therapeutic target. Drug Discov Today. 2004; 9: 704 – 711.
Ho T.K., Rajkumar V, Ponticos M, et al. Increased endogenous angiogenic response and hypoxia-inducible factor-1α in human critical limb ischemia. J Vasc Surg. 2006; 43: 125 – 133.